secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-032187
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q3 revenue $8.2M (+2%), adjusted EBITDA positive; going concern removed
--------------------------------------------------------------------------------

- Q3 revenue $8.2M, up 2% YoY; gross margin improved to 58% from 55%.
- Adjusted EBITDA positive $0.1M vs -$0.2M prior year; loss from continuing ops $1.3M.
- Cash balance $6.3M (up from $3.2M); sale of Pharma business removed going concern.
- ThyGeNEXT pricing change reduced revenue and EBITDA by ~$1.4M in Q3.
- Nine-month revenue $23.5M (-2%); loss from continuing ops improved to -$4.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222032187/0001493152-22-032187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222032187/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer